There are currently 15 active clinical trials seeking participants for Hepatitis B research studies. The states with the highest number of trials for Hepatitis B participants are California, New York, Beijing and Baden-Wuerttemberg.
Evaluation of Patients With Liver Disease
NCT00001971
Recruiting
The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver. Patients participating in the study will first undergo a routine check-up as an outpatient. They will be asked to provide blood and urine samples for laboratory testing and will undergo an ultrasound of the liver. Ultrasound examinations use sound waves to determine the size and texture of the liver. After th... Read More
Gender:
ALL
Ages:
Between 2 years and 100 years
Trial Updated:
05/02/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Liver Disease, Hepatitis D, Hepatitis C, Hepatitis B
Register for Updates
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
NCT03692897
Recruiting
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical q... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Banner University Medical Center Phoenix, Phoenix, Arizona +30 locations
Conditions: Hepatitis B, Hepatitis, Liver Diseases
Register for Updates
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504
Recruiting
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: GSK Investigational Site, Bakersfield, California +49 locations
Conditions: Hepatitis B
Register for Updates
Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
NCT06422767
Recruiting
This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo. The data generated will be used to model the relationship between bepirovirsen concentration and QTcF.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/14/2025
Locations: GSK Investigational Site, Austin, Texas
Conditions: Hepatitis B
Register for Updates
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859
Recruiting
This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in this study after completing the end of study (EoS) visit in the respective parent bepirovirsen studies (studies B-Clear \[209668: NCT04449029\], B-Together \[209348: NCT04676724\], B-F... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: GSK Investigational Site, Sacramento, California +50 locations
Conditions: Hepatitis B
Register for Updates
National Liver Cancer Screening Trial
NCT06084234
Recruiting
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), an... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/03/2025
Locations: University of Southern California, Los Angeles, California +13 locations
Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Register for Updates
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.
NCT00404989
Recruiting
The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major teratogenic effect involving any of the Registry drugs when administered to pregnant people. Registration is voluntary and confidential with information obtained from the health care provider. A Registry-assigned identifier allows for follow-up capability. Information on subjects is provided to the Registry prospectively (prior to the outcome of pregnancy being known) through their health care provider, with f... Read More
Gender:
FEMALE
Ages:
Between 12 years and 60 years
Trial Updated:
03/26/2025
Locations: Registry Coordinating Center, Wilmington, North Carolina
Conditions: HIV Infections, Hepatitis B
Register for Updates
HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers
NCT05272735
Recruiting
Antibodies are the primary mediators of the protection against infection provided by vaccination. Antibodies become most powerful after the B cells that produce them undergo an evolutionary process called affinity maturation, in which antibodies increase their ability to bind to their targets, and thus neutralize pathogens. Affinity maturation occurs in structures within secondary lymphoid organs (for example lymph nodes or tonsils) known as germinal centers. Germinal centers are well known to b... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/18/2025
Locations: The Rockefeller University, New York, New York
Conditions: Hepatitis B
Register for Updates
HepB MAb19 in Individuals with Chronic Hepatitis B Infection
NCT05856890
Recruiting
This is a first-in-human, placebo-controlled, single dose, dose-escalation phase 1 study to evaluate the safety, pharmacokinetics and antiviral activity of a highly potent neutralizing anti-HBV monoclonal antibody (mAb), HepB mAb19, which targets the S-protein in individuals with chronic hepatitis B (CHB) on nucleos(t)ide analog therapy (NRTI).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/23/2025
Locations: NYU Langone Health, New York, New York +1 locations
Conditions: Hepatitis b Virus, Hepatitis B
Register for Updates
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414
Recruiting
The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced therapy with bepirovirsen for further clinical development and to assess the contribution of DAP/TOM to the sequential regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: GSK Investigational Site, San Francisco, California +88 locations
Conditions: Chronic Hepatitis B Virus Infection, Hepatitis B
Register for Updates
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
NCT04588077
Recruiting
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Arizona Health Research, Chandler, Arizona +71 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates